AU2008306455C1 - Novel siRNA structures - Google Patents
Novel siRNA structures Download PDFInfo
- Publication number
- AU2008306455C1 AU2008306455C1 AU2008306455A AU2008306455A AU2008306455C1 AU 2008306455 C1 AU2008306455 C1 AU 2008306455C1 AU 2008306455 A AU2008306455 A AU 2008306455A AU 2008306455 A AU2008306455 A AU 2008306455A AU 2008306455 C1 AU2008306455 C1 AU 2008306455C1
- Authority
- AU
- Australia
- Prior art keywords
- nucleotide
- modified
- seq
- nucleotides
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108020004459 Small interfering RNA Proteins 0.000 title abstract description 275
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 274
- 150000001875 compounds Chemical class 0.000 claims abstract description 219
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 59
- 201000010099 disease Diseases 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000003937 drug carrier Substances 0.000 claims abstract description 15
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 634
- 239000002773 nucleotide Substances 0.000 claims description 499
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 266
- 208000035657 Abasia Diseases 0.000 claims description 101
- 230000000692 anti-sense effect Effects 0.000 claims description 101
- 239000002336 ribonucleotide Substances 0.000 claims description 101
- 235000000346 sugar Nutrition 0.000 claims description 98
- 108091034117 Oligonucleotide Proteins 0.000 claims description 97
- 108091028664 Ribonucleotide Proteins 0.000 claims description 96
- 108020004999 messenger RNA Proteins 0.000 claims description 71
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 65
- 208000033626 Renal failure acute Diseases 0.000 claims description 65
- 201000011040 acute kidney failure Diseases 0.000 claims description 65
- 208000012998 acute renal failure Diseases 0.000 claims description 63
- 230000000295 complement effect Effects 0.000 claims description 55
- 238000002054 transplantation Methods 0.000 claims description 51
- 108091081021 Sense strand Proteins 0.000 claims description 38
- 208000016354 hearing loss disease Diseases 0.000 claims description 37
- 210000004072 lung Anatomy 0.000 claims description 36
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 33
- 206010011878 Deafness Diseases 0.000 claims description 32
- 208000010412 Glaucoma Diseases 0.000 claims description 31
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 31
- 231100000888 hearing loss Toxicity 0.000 claims description 30
- 230000010370 hearing loss Effects 0.000 claims description 30
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 29
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 28
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 28
- 208000002780 macular degeneration Diseases 0.000 claims description 28
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 27
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 27
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical group O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims description 26
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 26
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 25
- 230000006378 damage Effects 0.000 claims description 24
- 208000014674 injury Diseases 0.000 claims description 21
- 210000003734 kidney Anatomy 0.000 claims description 21
- 208000020431 spinal cord injury Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- 206010063837 Reperfusion injury Diseases 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 18
- 239000010452 phosphate Substances 0.000 claims description 18
- 208000003265 stomatitis Diseases 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 15
- 230000000302 ischemic effect Effects 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 14
- 206010013774 Dry eye Diseases 0.000 claims description 14
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 13
- 210000000056 organ Anatomy 0.000 claims description 13
- 210000002216 heart Anatomy 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 206010029350 Neurotoxicity Diseases 0.000 claims description 7
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 7
- 230000007135 neurotoxicity Effects 0.000 claims description 7
- 231100000228 neurotoxicity Toxicity 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 abstract description 52
- 238000011282 treatment Methods 0.000 abstract description 41
- 230000004048 modification Effects 0.000 description 130
- 238000012986 modification Methods 0.000 description 130
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 69
- 102100032616 Caspase-2 Human genes 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 61
- 101000867612 Homo sapiens Caspase-2 Proteins 0.000 description 60
- -1 LRDD Proteins 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 53
- 101000755529 Homo sapiens Transforming protein RhoA Proteins 0.000 description 48
- 102100022387 Transforming protein RhoA Human genes 0.000 description 48
- 102000039446 nucleic acids Human genes 0.000 description 48
- 108020004707 nucleic acids Proteins 0.000 description 48
- 102000004196 processed proteins & peptides Human genes 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 46
- 150000007523 nucleic acids Chemical group 0.000 description 43
- 239000005547 deoxyribonucleotide Substances 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 42
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 37
- 102000040430 polynucleotide Human genes 0.000 description 36
- 108091033319 polynucleotide Proteins 0.000 description 36
- 239000002157 polynucleotide Substances 0.000 description 36
- 230000005764 inhibitory process Effects 0.000 description 35
- 102100029592 Activator of apoptosis harakiri Human genes 0.000 description 33
- 101000987827 Homo sapiens Activator of apoptosis harakiri Proteins 0.000 description 33
- 125000002619 bicyclic group Chemical group 0.000 description 33
- 229920002477 rna polymer Polymers 0.000 description 30
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 27
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 27
- 102100025620 Cytochrome b-245 light chain Human genes 0.000 description 26
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 26
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 26
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 25
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 25
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 description 24
- 101000856723 Homo sapiens Cytochrome b-245 light chain Proteins 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 24
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 24
- 230000000861 pro-apoptotic effect Effects 0.000 description 24
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 23
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-altritol Chemical class OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 22
- 102000053602 DNA Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 22
- 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 description 22
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 22
- 102100021218 Dual oxidase 1 Human genes 0.000 description 21
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 20
- 108700012928 MAPK14 Proteins 0.000 description 20
- 102000004264 Osteopontin Human genes 0.000 description 20
- 108010081689 Osteopontin Proteins 0.000 description 20
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 19
- 102100031168 CCN family member 2 Human genes 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- 102100032347 Poly(ADP-ribose) glycohydrolase Human genes 0.000 description 19
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 19
- 230000009368 gene silencing by RNA Effects 0.000 description 19
- 108010078356 poly ADP-ribose glycohydrolase Proteins 0.000 description 19
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 description 18
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 description 18
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 18
- 238000010171 animal model Methods 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 18
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 17
- 108010083068 Dual Oxidases Proteins 0.000 description 17
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 17
- 101150095096 TRPM2 gene Proteins 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 16
- 208000028867 ischemia Diseases 0.000 description 16
- 210000001328 optic nerve Anatomy 0.000 description 16
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 102000003615 TRPM2 Human genes 0.000 description 15
- 210000003477 cochlea Anatomy 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 14
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 description 14
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 108091012583 BCL2 Proteins 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 101000740725 Homo sapiens Complement component 1 Q subcomponent-binding protein, mitochondrial Proteins 0.000 description 12
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 12
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000002103 transcriptional effect Effects 0.000 description 11
- 208000021709 Delayed Graft Function Diseases 0.000 description 10
- 208000009386 Experimental Arthritis Diseases 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 10
- 108091093037 Peptide nucleic acid Proteins 0.000 description 10
- 102100031234 Transient receptor potential cation channel subfamily M member 2 Human genes 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000002768 hair cell Anatomy 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 108090000668 Annexin A2 Proteins 0.000 description 9
- 206010011903 Deafness traumatic Diseases 0.000 description 9
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 9
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 9
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 8
- 102100034613 Annexin A2 Human genes 0.000 description 8
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 7
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 7
- 102100029826 Reticulon-4 receptor Human genes 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 210000002592 gangliocyte Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 6
- 102000004149 Annexin A2 Human genes 0.000 description 6
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 6
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 description 6
- 101000976900 Homo sapiens Mitogen-activated protein kinase 14 Proteins 0.000 description 6
- 101000844507 Homo sapiens Transient receptor potential cation channel subfamily M member 2 Proteins 0.000 description 6
- 101001129796 Homo sapiens p53-induced death domain-containing protein 1 Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108010041199 Nogo Receptor 1 Proteins 0.000 description 6
- 108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 6
- 102100026058 Oligodendrocyte transcription factor 2 Human genes 0.000 description 6
- 102100026056 Oligodendrocyte transcription factor 3 Human genes 0.000 description 6
- 101710195927 Oligodendrocyte transcription factor 3 Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 101710187864 TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 230000002970 ototoxic effect Effects 0.000 description 6
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000700114 Chinchillidae Species 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 5
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 5
- 208000004852 Lung Injury Diseases 0.000 description 5
- 208000021320 Nasu-Hakola disease Diseases 0.000 description 5
- 206010029155 Nephropathy toxic Diseases 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 206010069363 Traumatic lung injury Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 231100000515 lung injury Toxicity 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 230000007694 nephrotoxicity Effects 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 102100031691 p53-induced death domain-containing protein 1 Human genes 0.000 description 5
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- 108091027075 5S-rRNA precursor Proteins 0.000 description 4
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 101150044146 CASP2 gene Proteins 0.000 description 4
- 108050001175 Connexin Proteins 0.000 description 4
- 108010069241 Connexin 43 Proteins 0.000 description 4
- 208000025962 Crush injury Diseases 0.000 description 4
- 102100025287 Cytochrome b Human genes 0.000 description 4
- 108010075028 Cytochromes b Proteins 0.000 description 4
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 4
- 101150028113 Hrk gene Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000004722 NADPH Oxidases Human genes 0.000 description 4
- 108010002998 NADPH Oxidases Proteins 0.000 description 4
- 102100021874 NADPH oxidase 3 Human genes 0.000 description 4
- 102100040557 Osteopontin Human genes 0.000 description 4
- 206010033109 Ototoxicity Diseases 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000003376 axonal effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000003027 ear inner Anatomy 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 210000000067 inner hair cell Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000013059 nephrectomy Methods 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 210000003733 optic disk Anatomy 0.000 description 4
- 231100000199 ototoxic Toxicity 0.000 description 4
- 231100000262 ototoxicity Toxicity 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 101150055869 25 gene Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 108090000552 Caspase-2 Proteins 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 241000700112 Chinchilla Species 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 3
- 101710190086 Cytochrome b-245 light chain Proteins 0.000 description 3
- 102000010170 Death domains Human genes 0.000 description 3
- 108050001718 Death domains Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 3
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 3
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 3
- 101100256651 Homo sapiens SENP6 gene Proteins 0.000 description 3
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108050002571 NADPH oxidase 3 Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100026073 Oligodendrocyte transcription factor 1 Human genes 0.000 description 3
- 101710195940 Oligodendrocyte transcription factor 1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 206010063897 Renal ischaemia Diseases 0.000 description 3
- 102000042463 Rho family Human genes 0.000 description 3
- 108091078243 Rho family Proteins 0.000 description 3
- 101150038317 SSP1 gene Proteins 0.000 description 3
- 101100125020 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pss1 gene Proteins 0.000 description 3
- 101100018019 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ssc1 gene Proteins 0.000 description 3
- 102100023713 Sentrin-specific protease 6 Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 101710123685 Transient receptor potential cation channel subfamily M member 2 Proteins 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- MEUIIHOXOWVKNP-UHFFFAOYSA-N phosphanylformic acid Chemical class OC(P)=O MEUIIHOXOWVKNP-UHFFFAOYSA-N 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 101150098072 20 gene Proteins 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 2
- 101710091620 Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108091005462 Cation channels Proteins 0.000 description 2
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108091093094 Glycol nucleic acid Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- 101001059644 Homo sapiens MAP kinase-activating death domain protein Proteins 0.000 description 2
- 101100291373 Homo sapiens MAPK14 gene Proteins 0.000 description 2
- 101000727477 Homo sapiens Reticulon-4 receptor Proteins 0.000 description 2
- 101000674731 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102100028822 MAP kinase-activating death domain protein Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 206010036626 Presbyacusis Diseases 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- 108010080192 Purinergic Receptors Proteins 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 101150058540 RAC1 gene Proteins 0.000 description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010039203 Road traffic accident Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006097 Spinal Dysraphism Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 102100021228 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Human genes 0.000 description 2
- 108091046915 Threose nucleic acid Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 2
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 2
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 description 2
- 101710174937 Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- IMBYBANOLUYVCT-CRCLSJGQSA-N [(2r,3s)-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound OC[C@H]1OCC[C@@H]1OP(O)(O)=O IMBYBANOLUYVCT-CRCLSJGQSA-N 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000005122 aminoalkylamino group Chemical group 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 150000008209 arabinosides Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000016532 chronic granulomatous disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 210000002266 hair cells auditory Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 208000009800 presbycusis Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- YROJWWHYHBKDPB-VEGRVEBRSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanal;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical group OP(O)(O)=S.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O YROJWWHYHBKDPB-VEGRVEBRSA-N 0.000 description 1
- FPHJJCBLRAPJQJ-CRKDRTNXSA-N (2s,3r,4s,5r)-2-amino-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(N)O[C@H](CO)[C@@H](O)[C@H]1O FPHJJCBLRAPJQJ-CRKDRTNXSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical compound NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 description 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- NXEGRTVWWNBQLW-UHFFFAOYSA-N 12-aminododecyl dihydrogen phosphate Chemical compound NCCCCCCCCCCCCOP(O)(O)=O NXEGRTVWWNBQLW-UHFFFAOYSA-N 0.000 description 1
- WYDKPTZGVLTYPG-UHFFFAOYSA-N 2,8-diamino-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(N)N2 WYDKPTZGVLTYPG-UHFFFAOYSA-N 0.000 description 1
- AKEMIRQFANFFKU-NCYRAAIKSA-N 2-[[(2s,4as,6ar,6as,6br,8ar,10s,12as)-10-(2-carboxybenzoyl)oxy-2,4a,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12-dodecahydropicen-2-yl]methoxycarbonyl]benzoic acid Chemical compound C([C@]1(C)CC2=C3[C@@]([C@@]4(CC[C@H]5C(C)(C)[C@@H](OC(=O)C=6C(=CC=CC=6)C(O)=O)CC[C@]5(C)[C@H]4C=C3)C)(C)CC[C@@]2(C)CC1)OC(=O)C1=CC=CC=C1C(O)=O AKEMIRQFANFFKU-NCYRAAIKSA-N 0.000 description 1
- YKJZFNRWSLHRAG-UHFFFAOYSA-N 2-phosphanylacetic acid Chemical class OC(=O)CP YKJZFNRWSLHRAG-UHFFFAOYSA-N 0.000 description 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2h-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 description 1
- XZWMZFQOHTWGQE-UHFFFAOYSA-N 6-azathymine Chemical compound CC1=NNC(=O)NC1=O XZWMZFQOHTWGQE-UHFFFAOYSA-N 0.000 description 1
- PFUVOLUPRFCPMN-UHFFFAOYSA-N 7h-purine-6,8-diamine Chemical compound C1=NC(N)=C2NC(N)=NC2=N1 PFUVOLUPRFCPMN-UHFFFAOYSA-N 0.000 description 1
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 1
- 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 101710163391 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase Proteins 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000237967 Aplysia Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101000881293 Arabidopsis thaliana Serine/arginine-rich-splicing factor SR34 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- 101100268548 Caenorhabditis elegans apl-1 gene Proteins 0.000 description 1
- 101100350997 Caenorhabditis elegans parg-2 gene Proteins 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 101710174880 Capsid vertex protein Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100024931 Caspase-14 Human genes 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 101150091877 Ccn2 gene Proteins 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 206010011894 Deafness permanent Diseases 0.000 description 1
- 101000929043 Dermatophagoides pteronyssinus Mite allergen Der p 6 Proteins 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000006265 Dual Oxidases Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710181040 Endonuclease 5 Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000089409 Erythrina poeppigiana Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000761467 Homo sapiens Caspase-14 Proteins 0.000 description 1
- 101000766989 Homo sapiens Claudin-11 Proteins 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000974918 Homo sapiens Cyclic AMP-dependent transcription factor ATF-3 Proteins 0.000 description 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 1
- 101001021404 Homo sapiens G-protein coupled receptor-associated sorting protein 2 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 description 1
- 101001032567 Homo sapiens Glycogen synthase kinase-3 beta Proteins 0.000 description 1
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101001108225 Homo sapiens NADPH oxidase 3 Proteins 0.000 description 1
- 101100240829 Homo sapiens NOX3 gene Proteins 0.000 description 1
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 1
- 101100351000 Homo sapiens PARG gene Proteins 0.000 description 1
- 101100139835 Homo sapiens RAC1 gene Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 101100364398 Homo sapiens RTN4R gene Proteins 0.000 description 1
- 101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 101100370896 Homo sapiens TRPM2 gene Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101001131742 Leishmania amazonensis Probable quinone oxidoreductase Proteins 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 101000959200 Lytechinus pictus Actin, cytoskeletal 2 Proteins 0.000 description 1
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 101100348498 Medicago truncatula NGR gene Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101100219978 Mus musculus Ccn2 gene Proteins 0.000 description 1
- 101000880403 Mus musculus Metalloreductase STEAP4 Proteins 0.000 description 1
- 101000613819 Mus musculus Osteopontin Proteins 0.000 description 1
- 101001060853 Mus musculus Ras-related protein Rab-34 Proteins 0.000 description 1
- 101000607577 Mus musculus Unknown protein from 2D-PAGE of fibroblasts Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 1
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 102100021873 NADPH oxidase 1 Human genes 0.000 description 1
- MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100023206 Neuromodulin Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 102000005781 Nogo Receptor Human genes 0.000 description 1
- 102000000343 Nogo Receptor 1 Human genes 0.000 description 1
- 108020003872 Nogo receptor Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 1
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 101710091132 Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 102000042326 STEAP family Human genes 0.000 description 1
- 108091077778 STEAP family Proteins 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100026102 Short transient receptor potential channel 7 Human genes 0.000 description 1
- 101710173698 Short transient receptor potential channel 7 Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101710200742 Tail assembly protein Gp24 Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101150033973 Trpc7 gene Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 102100020722 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 Human genes 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 101000920091 Xenopus laevis Elongation factor 1-delta Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 201000011348 autosomal recessive nonsyndromic deafness 38 Diseases 0.000 description 1
- 208000032990 autosomal recessive nonsyndromic hearing loss 38 Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011263 bladder neck cancer Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000043255 human ANXA2 Human genes 0.000 description 1
- 102000046837 human ATF3 Human genes 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 102000057809 human BNIP3 Human genes 0.000 description 1
- 102000052982 human C1QBP Human genes 0.000 description 1
- 102000052835 human CASP2 Human genes 0.000 description 1
- 102000052645 human CD38 Human genes 0.000 description 1
- 102000046983 human CYBA Human genes 0.000 description 1
- 102000049576 human DUOX1 Human genes 0.000 description 1
- 102000048346 human GSK3B Human genes 0.000 description 1
- 102000055553 human HRK Human genes 0.000 description 1
- 102000053195 human P2RX7 Human genes 0.000 description 1
- 102000043374 human PIDD1 Human genes 0.000 description 1
- 102000056857 human RAC1 Human genes 0.000 description 1
- 102000048282 human RHOA Human genes 0.000 description 1
- 102000048720 human RTN4R Human genes 0.000 description 1
- 102000051312 human SPP1 Human genes 0.000 description 1
- 102000048782 human STEAP4 Human genes 0.000 description 1
- 102000045119 human TRPM2 Human genes 0.000 description 1
- 102000045892 human TYROBP Human genes 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010075796 liver regeneration factor 1 Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 231100000637 nephrotoxin Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002985 organ of corti Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000041788 p53 family Human genes 0.000 description 1
- 108091075611 p53 family Proteins 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- RHDXSLLGPJSSGW-VEGRVEBRSA-N phosphoric acid;(2r,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O RHDXSLLGPJSSGW-VEGRVEBRSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 108010087917 rhoA GTP Binding Protein Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001079 scala tympani Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000001323 spiral ganglion Anatomy 0.000 description 1
- 101150063780 spp1 gene Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 210000003863 superior colliculi Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99757607P | 2007-10-03 | 2007-10-03 | |
| US60/997,576 | 2007-10-03 | ||
| US66407P | 2007-10-25 | 2007-10-25 | |
| US61/000,664 | 2007-10-25 | ||
| US353507P | 2007-11-15 | 2007-11-15 | |
| US61/003,535 | 2007-11-15 | ||
| US1004008P | 2008-01-04 | 2008-01-04 | |
| US61/010,040 | 2008-01-04 | ||
| US12851908P | 2008-05-22 | 2008-05-22 | |
| US61/128,519 | 2008-05-22 | ||
| US13463808P | 2008-07-10 | 2008-07-10 | |
| US61/134,638 | 2008-07-10 | ||
| US18903508P | 2008-08-15 | 2008-08-15 | |
| US61/189,035 | 2008-08-15 | ||
| PCT/IL2008/001197 WO2009044392A2 (en) | 2007-10-03 | 2008-09-04 | Novel sirna structures |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2008306455A1 AU2008306455A1 (en) | 2009-04-09 |
| AU2008306455B2 AU2008306455B2 (en) | 2013-08-22 |
| AU2008306455C1 true AU2008306455C1 (en) | 2014-04-17 |
Family
ID=40526792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008306455A Ceased AU2008306455C1 (en) | 2007-10-03 | 2008-09-04 | Novel siRNA structures |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8614309B2 (https=) |
| EP (1) | EP2231168A4 (https=) |
| JP (2) | JP5646997B2 (https=) |
| KR (1) | KR20100085951A (https=) |
| CN (2) | CN101815521B (https=) |
| AU (1) | AU2008306455C1 (https=) |
| BR (1) | BRPI0817605A2 (https=) |
| CA (1) | CA2701845A1 (https=) |
| RU (1) | RU2487716C2 (https=) |
| WO (1) | WO2009044392A2 (https=) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US20100292301A1 (en) * | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
| EP2242854A4 (en) * | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | COMPOUNDS AND USES THEREOF |
| CA2715289C (en) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
| CA2718765A1 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | Novel sirna compounds for inhibiting rtp801 |
| EP2285385A4 (en) * | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | COMPOUNDS BASED ON RNSI TO INHIBIT NRF2 |
| WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| NZ601660A (en) | 2008-08-25 | 2014-05-30 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| CA2962219C (en) * | 2008-10-22 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
| WO2010046889A1 (en) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for delivery of sirna to bone marrow cells and uses thereof |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| CN102458418B (zh) * | 2009-06-08 | 2015-09-16 | 夸克制药公司 | 一种寡核苷酸化合物的制药用途 |
| EP2264169A1 (en) * | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
| GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| WO2011057171A1 (en) | 2009-11-08 | 2011-05-12 | Quark Pharmaceuticals, Inc. | METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011072082A2 (en) * | 2009-12-09 | 2011-06-16 | Nitto Denko Corporation | Modulation of hsp47 expression |
| EP2862929B1 (en) | 2009-12-09 | 2017-09-06 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating diseases, disorders or injury of the CNS |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| EP3560503B1 (en) | 2010-03-24 | 2021-11-17 | Phio Pharmaceuticals Corp. | Rna interference in dermal and fibrotic indications |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CN103097534B (zh) * | 2010-06-24 | 2017-07-28 | 夸克制药公司 | 针对rhoa的双链rna化合物及其用途 |
| US9243246B2 (en) * | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
| GB201015974D0 (en) * | 2010-09-23 | 2010-11-03 | Univ Warwick | Sirna |
| DK2631291T3 (da) | 2010-10-22 | 2019-06-11 | Olix Pharmaceuticals Inc | Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf |
| AU2011338682B2 (en) * | 2010-12-06 | 2017-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising threose modifications |
| PT2670411T (pt) | 2011-02-02 | 2019-06-18 | Excaliard Pharmaceuticals Inc | Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| CA2828544A1 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| AU2012332517B9 (en) | 2011-11-03 | 2017-08-10 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
| EP2800812A1 (en) | 2012-01-04 | 2014-11-12 | Quark Pharmaceuticals, Inc. | Double-stranded rna compounds to casp2 and uses thereof |
| CN102743763B (zh) * | 2012-04-11 | 2013-11-06 | 中山大学中山眼科中心 | 一种治疗青光眼的药物 |
| CN102703508A (zh) * | 2012-05-18 | 2012-10-03 | 边红 | 靶向GSK3β基因RNA干扰重组慢病毒载体及其构建、筛选方法 |
| KR101567576B1 (ko) * | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
| EP2895607B1 (en) | 2012-09-12 | 2021-05-05 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
| US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
| CN102911940B (zh) * | 2012-10-11 | 2014-02-05 | 江苏省疾病预防控制中心 | 特异性抑制nk细胞受体kir3dl1的小核酸干扰分子及其应用 |
| CA2900238A1 (en) * | 2013-02-22 | 2014-08-28 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
| EP3027223A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| CN105452465B (zh) | 2013-07-31 | 2019-06-21 | 奇比艾企业有限公司 | 鞘脂-聚烷基胺-寡核苷酸化合物 |
| US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| EP2865758A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
| EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
| EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| CA2949109A1 (en) * | 2014-05-29 | 2015-12-03 | Quark Pharmaceuticals, Inc. | Methods and compositions for preventing ischemia reperfusion injury in organs |
| WO2015191795A1 (en) * | 2014-06-12 | 2015-12-17 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| EP3862005A1 (en) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| US10752896B2 (en) | 2015-09-08 | 2020-08-25 | Sylentis Sau | siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| CN109072242A (zh) * | 2016-02-23 | 2018-12-21 | 科罗拉多州立大学董事会法人团体 | 用于治疗神经损伤的基于肽的方法 |
| JP7049262B2 (ja) | 2016-04-11 | 2022-04-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| CA3033867A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3564373A4 (en) * | 2016-12-28 | 2020-12-16 | Daiichi Sankyo Company, Limited | THERAPEUTIC DRUG FOR ALPORT SYNDROME |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| BR112022003513A2 (pt) * | 2019-08-27 | 2022-05-17 | Silence Therapeutics Gmbh | Ácidos nucleicos para inibição da expressão de c3 em uma célula |
| KR102757180B1 (ko) * | 2019-11-22 | 2025-01-21 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| CA3175691A1 (en) * | 2020-04-17 | 2021-10-21 | Neil R. Cashman | Compositions and methods for inhibiting tdp-43 and fus aggregation |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| KR20240014109A (ko) * | 2021-05-27 | 2024-01-31 | 알닐람 파마슈티칼스 인코포레이티드 | 탄산 무수화효소 2 발현을 침묵화하기 위한 조성물 및 방법 |
| EP4399217A2 (en) * | 2021-09-08 | 2024-07-17 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| JP2024539149A (ja) * | 2021-12-22 | 2024-10-28 | エヌエー ヴァクシン インスティテュート | 虚血・再灌流障害を予防または治療するための組成物及びその用途 |
| EP4560020A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| EP4560019A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| DE102024118456A1 (de) * | 2024-06-28 | 2025-12-31 | Eberhard Karls Universität Tübingen Medizinische Fakultät, Körperschaft des öffentlichen Rechts | Antisense-Oligonukleotide und deren Verwendung |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007091269A2 (en) * | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| WO1992001704A1 (en) | 1990-07-26 | 1992-02-06 | Koichi Shudo | Oligodeoxyribonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| WO1995000160A1 (en) | 1993-06-24 | 1995-01-05 | The General Hospital Corporation | Programmed cell death genes and proteins |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5858678A (en) | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| EP0799892A3 (en) | 1996-04-05 | 1998-08-12 | Takeda Chemical Industries, Ltd. | Calpain, its production and use |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| US5753789A (en) | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| US5929042A (en) | 1997-03-03 | 1999-07-27 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
| US7223856B2 (en) | 1997-03-03 | 2007-05-29 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| AU9016898A (en) | 1997-08-07 | 1999-03-01 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Methods and compositions for treatment of restenosis |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| DE69829857T2 (de) | 1997-08-21 | 2006-02-02 | Quark Biotech, Inc., Pleasanton | Hypoxie-regulierte gene |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
| US20030125277A1 (en) | 2001-11-08 | 2003-07-03 | Isis Pharmaceuticals Inc. | Antisense modulation of activating transcription factor 3 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| DK1146908T3 (da) | 1999-01-27 | 2005-10-10 | Becker David Dr | Formuleringer omfattende antisense-nukleotider mod connexiner |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
| US6140124A (en) | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
| KR20070118315A (ko) | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| AU6974900A (en) | 1999-09-07 | 2001-04-10 | University Health Network | A p53-induced protein with a death domain that can promote apoptosis |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| WO2001036641A2 (en) | 1999-11-02 | 2001-05-25 | Chiron Corporation | DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| US6323029B1 (en) | 2000-01-19 | 2001-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glycogen synthase kinase 3 beta expression |
| US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| AU2001289068A1 (en) | 2000-09-20 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 2 expression |
| FR2815541B1 (fr) | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| CA2452458A1 (en) * | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| GB0116955D0 (en) | 2001-07-11 | 2001-09-05 | Syngenta Ltd | Weed control process |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| EP1445312B1 (en) | 2001-11-21 | 2012-12-26 | Astellas Pharma Inc. | Method of inhibiting gene expression |
| EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| EP1495120B1 (en) | 2002-04-18 | 2012-10-10 | Acuity Pharmaceuticals, Inc | Means and methods for the specific modulation of target genes in the eye |
| US20040152650A1 (en) | 2002-07-22 | 2004-08-05 | Webster Keith A. | Preventing ischemia-induced cell damage |
| WO2004009797A2 (en) | 2002-07-23 | 2004-01-29 | Incyte Corporation | Protein modification and maintenance molecules |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| US20040142865A1 (en) | 2002-10-02 | 2004-07-22 | Weber Georg F. | Osteopontin-based cancer therapies |
| AU2003304386A1 (en) | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| AU2002952550A0 (en) | 2002-11-08 | 2002-11-21 | The University Of Queensland | Modulating TNFalpha Secretion |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| EP1626732B1 (en) | 2003-05-22 | 2013-04-03 | CHIESI FARMACEUTICI S.p.A. | Means for preventing and treating cellular death and their biological applications |
| PT1633767T (pt) | 2003-06-02 | 2019-02-27 | Univ Massachusetts | Métodos e composições para controlar a eficácia do silenciamento de arn |
| EP1633890B2 (en) | 2003-06-02 | 2020-11-18 | University of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES |
| US20080249038A1 (en) | 2003-10-07 | 2008-10-09 | Quark Biotech, Inc. | Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof |
| WO2005103297A1 (en) | 2004-03-31 | 2005-11-03 | Georgetown University | METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| EP1740614A2 (en) | 2004-04-30 | 2007-01-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
| WO2005110464A2 (en) * | 2004-05-14 | 2005-11-24 | Oregon Health & Science University | Irx5 inhibition as treatment for hyperproliferative disorders |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP2319925B1 (en) | 2004-08-16 | 2018-07-25 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
| AU2005288522B2 (en) * | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| AU2006272808C1 (en) * | 2005-07-21 | 2010-10-21 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of the Rho-A gene and uses thereof |
| AU2006279454B2 (en) * | 2005-08-17 | 2011-12-15 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
-
2008
- 2008-09-04 RU RU2010113514/10A patent/RU2487716C2/ru not_active IP Right Cessation
- 2008-09-04 CN CN200880110087.0A patent/CN101815521B/zh not_active Expired - Fee Related
- 2008-09-04 WO PCT/IL2008/001197 patent/WO2009044392A2/en not_active Ceased
- 2008-09-04 KR KR1020107009512A patent/KR20100085951A/ko not_active Ceased
- 2008-09-04 EP EP08808012A patent/EP2231168A4/en not_active Withdrawn
- 2008-09-04 CN CN201210369167.6A patent/CN103898110A/zh active Pending
- 2008-09-04 CA CA2701845A patent/CA2701845A1/en not_active Abandoned
- 2008-09-04 JP JP2010527594A patent/JP5646997B2/ja not_active Expired - Fee Related
- 2008-09-04 BR BRPI0817605A patent/BRPI0817605A2/pt not_active IP Right Cessation
- 2008-09-04 AU AU2008306455A patent/AU2008306455C1/en not_active Ceased
- 2008-09-04 US US12/733,998 patent/US8614309B2/en not_active Expired - Fee Related
-
2012
- 2012-08-27 US US13/595,519 patent/US20130123334A1/en not_active Abandoned
-
2014
- 2014-06-18 JP JP2014125717A patent/JP2014210789A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007091269A2 (en) * | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
Also Published As
| Publication number | Publication date |
|---|---|
| US8614309B2 (en) | 2013-12-24 |
| KR20100085951A (ko) | 2010-07-29 |
| RU2487716C2 (ru) | 2013-07-20 |
| US20110112168A1 (en) | 2011-05-12 |
| CN103898110A (zh) | 2014-07-02 |
| EP2231168A2 (en) | 2010-09-29 |
| RU2010113514A (ru) | 2011-11-10 |
| AU2008306455B2 (en) | 2013-08-22 |
| CN101815521B (zh) | 2014-12-10 |
| WO2009044392A2 (en) | 2009-04-09 |
| JP2011500003A (ja) | 2011-01-06 |
| AU2008306455A1 (en) | 2009-04-09 |
| CN101815521A (zh) | 2010-08-25 |
| JP2014210789A (ja) | 2014-11-13 |
| JP5646997B2 (ja) | 2014-12-24 |
| CA2701845A1 (en) | 2009-04-09 |
| EP2231168A4 (en) | 2012-01-04 |
| WO2009044392A3 (en) | 2010-03-04 |
| US20130123334A1 (en) | 2013-05-16 |
| BRPI0817605A2 (pt) | 2017-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008306455C1 (en) | Novel siRNA structures | |
| US9446062B2 (en) | Methods of treating ischemia-reperfusion injury with siRNAs | |
| US9249414B2 (en) | Oligonucleotide compounds comprising non-nucleotide overhangs | |
| JP2010507387A6 (ja) | 新規のｓｉＲＮＡおよびその使用方法 | |
| US20100273854A1 (en) | Compositions and methods for inhibiting nadph oxidase expression | |
| US20110028531A1 (en) | Novel sirna compounds for inhibiting rtp801 | |
| US20140350068A1 (en) | Rtp801l sirna compounds and methods of use thereof | |
| WO2009074990A2 (en) | Rtp801l sirna compounds and methods of use thereof | |
| HK1152235A (en) | Novel sirna compounds for inhibiting rtp801 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 DEC 2013 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 DEC 2013 |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |